Business context and reporting period
Ekso Bionics Holdings, Inc. (the issuer named in the filing; not “Chronoscale Holdings Corp.”) filed this unaudited Form 10-Q for the quarter ended September 30, 2016. It designs, develops, and sells medical and industrial exoskeletons and provides engineering services. Amounts below are in millions of dollars unless otherwise stated.
Financial performance and position
- Third-quarter revenue: $1.596 million, down 45% from $2.915 million a year earlier. Device and related revenue rose 37% to $1.495 million, including $0.4 million of industrial sales; engineering services revenue fell 94% to $0.101 million.
- Third-quarter profitability: Gross profit was $0.403 million (25.3% margin), versus $0.468 million (16.1%) a year earlier. Operating loss was $6.866 million versus $5.181 million; net loss was $8.478 million versus $5.185 million. A $3.016 million noncash preferred deemed dividend brought the loss applicable to common shareholders to $11.494 million, or $0.60 per basic share.
- Nine-month results: Revenue was $11.634 million, up 73%; gross profit was $2.104 million (18.1% margin), versus $1.373 million (20.4%). Operating loss widened to $20.904 million from $14.909 million. Net loss was $17.894 million versus $14.945 million; after a $10.345 million preferred deemed dividend, loss applicable to common shareholders was $28.239 million, or $1.67 per basic share.
- Cash flow and liquidity: Cash was $12.800 million at September 30, down from $19.552 million at year-end. Nine-month operating cash use was $20.555 million, investing cash use $0.728 million, and financing cash provided $14.537 million, primarily from the August stock offering. Current assets were $17.574 million and current liabilities $5.506 million. Management said resources, including subsequent warrant-exercise proceeds, were expected to fund obligations into the second quarter of 2017.
- Debt and obligations: The balance sheet reports $0.067 million of current capital lease obligations; lease and note disclosures show $0.166 million in present-value capital lease and note payments. The filing also lists $3.004 million of total contractual obligations, mainly facility leases and an Equipois supply commitment. The $6.165 million warrant liability is a fair-value liability, not borrowings.
Material changes versus prior comparable periods
- Nine-month device revenue included $6.517 million of revenue deferred before 2016, recognized following a change in the company’s revenue-recognition estimate. Associated cost of revenue was $4.159 million, adding $2.358 million to gross profit and reducing reported loss.
- For the quarter, lower engineering-services revenue was the main driver of the year-over-year revenue decline. Management said it shifted engineering resources toward internal development of home/wellness and industrial products.
- Operating expenses increased 29% in the quarter and 41% for nine months, reflecting expanded sales and marketing, research and development, and administrative costs.
- Nine-month results included a $3.030 million noncash gain from lower warrant fair value; third-quarter results included a $1.620 million noncash warrant revaluation loss. The company recorded a $0.911 million one-time charge for preventative maintenance and upgrades on pre-2016 devices, and $0.212 million of warranty expense.
- The August 2016 common-stock offering raised $14.694 million net. Its anti-dilution provisions adjusted the conversion terms of preferred shares and reduced the exercise price of certain warrants to $3.74. All preferred shares had been converted by September 30. The filing reports 21.393 million common shares outstanding at quarter-end and 21,880,959 as of November 2.
Outlook, risks, and unusual items
- No quantified revenue or earnings guidance was provided. Management expected modest revenue increases, alongside incremental sales, marketing, and R&D expense, and said significant additional financing would be required. It warned that financing may not be available on acceptable terms or at all; absent financing, it may need to cut discretionary costs or curtail operations, and equity financing could dilute shareholders.
- Ekso GT received FDA clearance in April 2016 for specified stroke and spinal-cord-injury uses; July labeling changes broadened the stroke indication. The company reported seven MDR-reportable device events since July 1, 2015, with no reported patient injuries; required reports were filed and the company described design, manufacturing, and maintenance changes.
- The company cited risks including regulatory approval, adoption and reimbursement, long and variable sales cycles, competition, clinical-trial outcomes, intellectual property, and access to capital. Management reported disclosure controls were effective and no material control changes occurred in the quarter.
- Subsequent to quarter-end, the company received $1.825 million through October 30 from exercises of 488 warrants. It also entered a five-year extension of its Richmond headquarters lease, beginning June 2017.
Important facts for investors to verify
- Confirm issuer identity and filing-period details, given the request metadata names a different company from the 10-Q.
- Assess the cash runway against actual operating cash burn and the timing and terms of future financing; management’s runway estimate extended only into Q2 2017.
- Separate underlying sales trends from the $6.517 million release of previously deferred revenue, and review how the new revenue-recognition estimate affects comparability.
- Track medical and industrial unit sales, gross margins, engineering-services decline, and whether rising operating expenses produce commercial growth.
- Review dilution and potential share overhang from outstanding warrants, options, and preferred-stock anti-dilution adjustments, as well as the sensitivity of warrant fair value to share price.
- Verify subsequent warrant proceeds, FDA/MDR developments, clinical-trial progress, and fixed lease, royalty, and supply commitments.